2011. 6.13. 소화기내과 김경엽 Gastroenterology 2011;140:1952-1960.

Slides:



Advertisements
Similar presentations
Liver Transplant Outcomes in the United States : Effect of Preservation Solution DKFC Symposium July 16, 2012 John Fung, MD, PhD Cleveland Clinic Disclosure:
Advertisements

© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.
CURRENT STATE OF LIVER ALLOCATION AND DISTRIBUTION John R. Lake, MD University of Minnesota Medical School.
Mayo Clinic College of Medicine
SRTR Transplant Benefit-Based Liver Allocation Robert M. Merion, MD, FACS OPTN/UNOS Liver Forum Atlanta, GA April 12, 2010.
Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine.
Hepatitis web study H EPATITIS C C URRICULUM Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah.
OPTN Session 3 OPTN Policy Development and Feedback from RFI / Highlights of concepts being explored April 12, 2010.
Historical Perspective of Liver Allocation/Distribution Russell H. Wiesner, MD Professor of Medicine Mayo Clinic College of Medicine.
The Relationship Between CMS Quality Indicators and Long-term Outcomes Among Hospitalized Heart Failure Patients Mark Patterson, Ph.D., M.P.H. Post-doctoral.
Presented by Grace Diehl & JJ Trout February 25, 2013 Mathur, A.K., Heimbach, J., Steffick, D.E., Sonnenday, C.J., Goodrich, N.P. & Merion, R.M. (2010).
CREATININE AND CYSTATIN-C BASED GFRs VS 51 Cr-EDTA GFR IN PATIENTS WITH DECOMPENSATED CIRRHOSIS 1 4th Department of Internal Medicine, Hippokration General.
Notes on Logistic Regression STAT 4330/8330. Introduction Previously, you learned about odds ratios (OR’s). We now transition and begin discussion of.
Estimated GFR Based on Creatinine and Cystatin C
Assessment of Lupus (SLE) Mortality in a Patient-Based Community Data Bank Frederick Wolfe 1, Kaleb Michaud 1,2, Tracy Li 3, Robert S. Katz 4 1 National.
Kidney Transplant: A Realistic Chance for Elderly Patients Reference: Munnapradist S, Danovitch GM. Kidney transplants for the elderly: Hope or hype? Clin.
Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.
Periportal Fibrosis Without Cirrhosis Does Not Affect Outcomes Following Continuous Flow Ventricular Assist Device Implantation Jonathon E. Sargent, BS,
Complete Recovery of Renal Function After Acute Kidney Injury is Associated with Long-Term All-Cause Mortality In a Large Managed Care Organization Jennifer.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Institute Institute of Cardiovascular Diseases Prof Dr George IM Georgescu, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania WC. Hsieh,
實習生 : 中山醫 李佳靜 指導老師 : 陳燕慈 營養師 The Relationship of BMI and Lung Transplant Recipients 1.
Survival Analysis 1 Always be contented, be grateful, be understanding and be compassionate.
OPTN Proposal to Revise the Lung Allocation Score (LAS) System and Salient Activities of the Thoracic Organ Transplantation Committee.
Evaluating Risk Adjustment Models Andy Bindman MD Department of Medicine, Epidemiology and Biostatistics.
THE EFFECT OF TIMING OF INITITIATION OF CRRT ON PATIENTS REQUIRING EXTRA-CORPOREAL MEMBRANE OXYGENATION (ECMO) Asif Mansuri, MD, MRCPI Fellow, Division.
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
Acute On Chronic Liver Failure- Evolution of Concept 23 October 2015.
Andreas A. Rostved, MD Research assistant Department of Surgical Gastroenterology and Transplantation Rigshospitalet – Copenhagen University Hospital Denmark.
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
DONOR RISK INDEX-LIVER GRAFT SURVIVAL ASSOCIATION IN PATIENTS OVER 18 YEARS OF AGE IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.
What happens to patients returning to dialysis after transplant failure? Data from the UK Renal Registry Dr Lynsey Webb 1, Dr Anna Casula 1, Dr Charlie.
A2ALL When Using A2ALL Slides We welcome the use of A2ALL slides, as we value the distribution of our research for the benefit of patient care and transplant.
Dominique Valla, Richard Moreau, and Didier Lebrec
내과 R1 문정락 / prof. 정경환 N Engl J Med 369;10 nejm.org 932 september 5, 2013.
Date of download: 7/2/2016 From: An Acute Change in Lung Allocation Score and Survival After Lung Transplantation: A Cohort Study Ann Intern Med. 2013;158(9):
SURVIVAL IN ADULTS UNDERGOING KIDNEY TRANSPLANT FROM CADAVERIC DONORS COMPARED WITH PATIENTS ON WAITING LIST IN ARGENTINA Bisigniano, Liliana.
Hepatitis B virus infection in renal transplant recipients
Total Occlusion Study of Canada (TOSCA-2) Trial
The ALERT Trial.
MELD Score, Listing for Liver Transplant, and Organ Allocation
Sum of serum n-3 fatty acids value might be correlated with residual living days in older adult patients with gastro-intestinal cancer Moeko Kitagawa1,
Volume 150, Issue 2, Pages e6 (February 2016)
Pancreas Transplantation Committee
Liver transplantation and PSC
Clinical outcome after SVR: Veterans Affairs
Copyright © 2006 American Medical Association. All rights reserved.
Liver Transplantation: 50 years
Liver only transplants in the UK Question 2: In terms of survival benefit.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Liver Transplant For Patients with PSC
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.
New Developments in Hepatorenal Syndrome
Evaluation of the Patient With HCV Infection
Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )
Changes to HCC Criteria for Auto Approval
Volume 117, Issue 2, Pages (August 1999)
New Model for End Stage Liver Disease Improves Prognostic Capability After Transjugular Intrahepatic Portosystemic Shunt  Jennifer Guy, Ma Somsouk, Stephen.
Volume 140, Issue 7, Pages (June 2011)
Volume 154, Issue 8, Pages e8 (June 2018)
Brandy R. Lu, Jane Gralla, Edwin Liu, Emily L. Dobyns, Michael R
Volume 155, Issue 5, Pages e3 (November 2018)
Published online September 20, 2017 by JAMA Surgery
Volume 140, Issue 7, Pages (June 2011)
Histologic Predictors of Fibrosis Progression in Liver Allografts in Patients With Hepatitis C Virus Infection  Zina Meriden, Kimberly A. Forde, Theresa.
PRESENTER: Quynh vu, pgy-2
Volume 156, Issue 5, Pages e3 (April 2019)
Volume 135, Issue 5, Pages (November 2008)
Donor Allocation Policy in the US
Presentation transcript:

소화기내과 김경엽 Gastroenterology 2011;140:

Background

Model for End Stage Liver Disease (MELD) –To predict mortality in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) procedures –Organ allocation in the United States MELD score = 11.2 x log e (INR) x log e (creatinine, mg/dL) x log e (bilirubin, mg/dL) The MELD system –15% reduction in mortality among wait-list registrants An updated MELD based on data from patients awaiting liver transplantation should improve mortality prediction and allocation efficiency

The addition of serum sodium (Na) improves survival prediction of the MELD score Scientific Registry of Transplant Recipients (SRTR) MELD –Derived and validated using SRTR data from –Re-estimated coefficients of the MELD variables –Eliminated upper and low bounds for each variable –Update of the MELD coefficients –Improved concordance of model prediction across all subsets of MELD scores

Objectives

Based on the latest data -> optimized the MELD coefficients, including re-examination of the lower and upper bounds for individual variables Whether inclusion of Na concentration still adds value when it is considered in the context of the optimized model Compared the performance of the final optimized model with that of existing models, including the current MELD score, the MELDNa score, and the SRTR MELD score Main outcomes measure was ability to predict 90-day mortality of patients on the liver transplantation wait list

Materials and Methods

Patient Data Data were obtained from the Organ Procurement and Transplantation Network through the Standard Transplant Analysis and Research file All patients newly registered on the liver transplant waiting list Jan. 1, 2005 – Dec. 31, 2008 All adults with cirrhosis listed for a first liver transplantation

Exclusion –Age younger than 18 years –Previous liver transplantation –Status 1 for acute liver failure –Primary (ie, heatocellular carcinoma or cholangiocarcinoma) or metastatic hepatic malignancies Predictor variables –Bilirubin, creatinine, INR, Na Main outcomes variable –Death on the waiting list within 90 days of listing

Statistical Analysis 4 consecutive years of Organ Procurement and Transplantation Network data –Model derivation dataset ( ) –Model validation dataset ( ) Cox regression models evaluating mortality within 90 days based on the MELD variables

MELD score = 11.2 x log e (INR) x log e (creatinine, mg/dL) x log e (bilirubin, mg/dL) MELDNa score = MELD – Na – [0.025 x MELD x (140 – Na)] –Na: 125 – 140 mEq/L SRTR MELD score = x log e (1 + creatinine) log e (1 + bilirubin) log e (1 + INR)

Results

Patient characteristics Total 28,131 registrants on the waiting list for liver transplantation –14,190 in the model development set ( ) –13,941 in the model validation set ( )

No clinically important differences in baseline characteristics between the derivation and validation cohorts

In the model derivation dataset (n=14,190) –7% died and 30% received a transplant within 90 days –64% remained on the waiting list 90 days after listing –20 (0.14%) withdrew from the list within 90 days In the model validation dataset (n=13,941) –7% died and 29% received a transplant within 90 days –64% remained on the waiting list 90 days after listing –38 (0.27%) withdrew from the list within 90 days

Optimizing the MELD Score Smoothing splines were used to determine the functional relationship between bilirubin, creatinine, and INR and the risk of death in the Cox model

A linear relationship in the Cox model with risk of death for a wide range of bilirubin values. The significance of bilirubin below the level of 1 mg/dL is questionable. Figure 1. The relation between risk of 90-day mortality and individual Model for End Stage Liver Disease (MELD) variables

0.8 Figure 1. The relation between risk of 90-day mortality and individual Model for End Stage Liver Disease (MELD) variables

Current MELD –Creatinine: 1.0 – 4.0 mg/dL ReFit MELD –Creatinine: 0.8 – 3.0 mg/dL This change would affect 2.2% of patients, who had serum creatinine > 3.0 mg/dL, but less than the previous bound of 4.0 mg/dL

Figure 1. The relation between risk of 90-day mortality and individual Model for End Stage Liver Disease (MELD) variables A new upper bound of 3.0 for INR

Current MELD –INR: 1.0 – ReFit MELD –INR: 1.0 – 3.0 This change would affect 3.6% of patients on the wait list

MELD score = 11.2 x log e (INR) x log e (creatinine, mg/dL) x log e (bilirubin, mg/dL) ReFit MELD score = x log e (INR c ) x log e (creatinine c, mg/dL) x log e (bilirubin c, mg/dL) bilirubin c = bilirubin bounded below by 1 mg/dL c creatinine c = creatinine capped by 0.8 mg/dL below and 3 mg/dL above patients receiving renal replacement therapy = Cr 3 mg/dL INR c = INR bounded by 1 below and 3 above

Incorporation of Na: ReFit MELDNa 125

Significant interaction between sodium and bilirubin –Serum bilirubin ↑ -> impact of Na on mortaliry ↓ –This interaction was most pronounced when serum bilirubin was between 1 and 20 mg/dL

Validation of ReFit MELD and ReFit MELDNa in comparison with existing models

Projected Impact of Utilizing ReFit MELDNa for Liver Allocation n=459 n=3,357 n=459n=10,125

Thus, implementation of the new score will affect 3.3% (459 of 13,941) of all wait-list registrants and 12.0% (459 of 3816) of all transplantations The 90-day Kaplan-Meier probability of mortality in the group than would be missed by the existing MELD but picked up by the refit MELDNa (left uper quadrant) was 15.6% compared to 7.2% in those who would have been favored by the existing MELD (log rank test P <.01) 324 deaths under the existing MELD vs. 295 under refit MELDNa within 90 days (P <.01)